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The current status of studies aimed at identifying and developing
therapies which specifically compromise the function of the
existing neovasculature in solid tumours has been reviewed
recently (Chaplin and Dougherty, 1999; Hayes et al, 1999).
Although evidence for the therapeutic potential of vascular
targeting approaches was first provided over 150 years ago, these
authors have highlighted the fact that over the last decade signific-
ant research effort has been afforded to the development of therap-
ies that specifically target and damage tumour neovasculature. In
considering drug-based approaches to vascular targeting, it is the
tubulin-binding agents that have emerged as major players. In
early studies with colchicine (Ludford, 1948) and podophyllotoxin
(Algire et al, 1955) and, more recently, with vinblastine and
vincristine (Baguley et al, 1991; Hill et al, 1993) definite anti-
vascular effects were recorded, but these were only achieved at
doses approaching the maximum tolerated dose (MTD). The intro-
duction of vinorelbine into the clinic in the mid 1980s and the
rapid recognition of its major clinical activities, as reviewed
recently (Johnson et al, 1996; Budman, 1997), has led to a resur-
gence of interest in the Vinca alkaloid family of anticancer agents.
Indeed, a newly identified derivative, vinflunine, with substitu-
tions in the little exploited region of the catharanthine moiety
obtained using superacid chemistry and involving the selective
introduction of two fluorine atoms at the 20¢ position and the
reduction of the 3¢,4¢ double bond (Fahy et al, 1997), is now under-
going Phase I clinical trials in Europe. 
This study was initiated to establish whether vinflunine, docu-
mented in terms of both survival prolongation and tumour growth
inhibition, as having definite superiority over vinorelbine in a
series of experimental animal tumour models (Kruczynski et al,
1998a; Hill et al, 1999), produced any effects on tumour vascula-
ture using the MAC 15A transplantable colon adenocarcinoma.
This model has previously been validated for evaluating vascular
therapies in preclinical studies (Cowen et al, 1995). Vincristine 
is included in the study as a control reference compound.
Observations were also made on the in vitro effects of vinflunine
on human umbilical vein endothelial cells (HUVECs). 
MATERIALS AND METHODS 
Drugs 
Vinflunine, vinorelbine and vincristine were provided by Pierre
Fabre Médicament (Castres, France) and were dissolved at the appro-
priate concentrations using sterile physiological saline and injected
intraperitoneally at a volume of 0.1 ml per 10 g body weight. 
Animals 
Pure strain male NMRI mice aged 6–8 weeks (B & K Universal,
Hull, UK) received CRM diet (SDS, Witham, Essex, UK) and
water ad libitum. Mice were kept in cages in an air-conditioned
room with regular alternating cycles of light and darkness. All
animal procedures were carried out under a project licence issued
by the Home Office, London, UK and UKCCCR Guidelines
(1998) were followed throughout. 
Tumour system 
MAC 15A, a rapidly growing poorly differentiated adenocarcin-
oma of the colon was used in this study (Phillips et al, 1988). MAC
15A cells were routinely maintained in tissue culture. Prior to
chemotherapy experiments, 1 ´ 106 cells in sterile saline were
injected subcutaneously into the flank of each mouse (Laws et al,
1995). 
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Chemotherapy began when the tumours had reached a size that
could be reliably measured i.e. 3–4 days after implantation. Test
compounds were administered by a single intraperitoneal injection
to groups of 10 mice and the effects of therapy were assessed by
daily 2-dimensional caliper measurements of the tumours. Tumour
volumes were calculated from the formula a2 ´ b/2, where a is the
smaller and b is the larger diameter of the tumour. Tumour
volumes were normalized with respect to their initial volumes,
graphs of the relative tumour volume against time were plotted and
Mann-Whitney U tests performed to determine the statistical
significance of any differences in growth rate (tumour-volume
doubling time) between control and treated groups. 
Histology 
At the end of the experiments the animals were killed and histo-
logical examination of the tumours was carried out. In addition,
two animals per treatment group were killed 24 hours after treat-
ment and their tumours were examined histologically. Drug
induced haemorrhagic necrosis was quantified using an image
analysis system (Seescan, Cambridge, UK). 
Vascular assessment 
In order to assess effects of treatment with vinflunine on functional
vasculature 5 groups of 12 tumour-bearing mice were set up. One
group was used as a control and the other 4 were treated with
different doses of vinflunine ranging from 10 to 50  mg kg–1. To
assess the vascular effects of vinorelbine two groups of tumour-
bearing mice were set up; one group as a control and the other
treated with 10 mg kg–1 vinorelbine. Treatment was initiated when
the tumours had reached a similar size to those used in the
chemotherapy experiments described above i.e. had an established
blood vasculature. Hoechst 33342 (bisBenzimide) was used to
assess functional tumour vasculature (Quinn et al, 1992; Cowen 
et al, 1995). This compound was dissolved in sterile saline and
injected intravenously via the tail vein at a dose of 40 mg kg–1, 2, 4,
6and 24 hours after vinflunine treatment or 2 hours after vinorel-
bine treatment. One minute after injection of the vascular marker
the mice were killed by cervical dislocation (3 mice at each time
point), dissected and the tumour resected. Tumours were wrapped
in aluminium foil and immediately immersed in liquid nitrogen
and stored at280˚C until sectioning. 
Frozen sections (7 mm) were cut on a cryostat (Bright Instrument
Co Ltd, Huntingdon, UK) and air-dried. 5 random sections were
obtained from each tumour and they were examined under UV illu-
mination using a Vickers microscope at a magnification of 250. The
fluorescent dye concentrates in the nuclei of the endothelial cells,
so functional vasculature may be observed as fluorescence and the
area of fluorescence was determined by counting the number of
positive squares using a 400 square graticule from 5 random fields
in each section. Comparisons were made between percentage
vasculature in control and treated tumours. 
HUVEC assays 
Primary endothelial cells derived from the human umbilical vein
(HUVECs, a gift from Dr A Graham, University of Bradford) were
cultured in Medium 199 supplemented with 10% human serum, 1
mM sodium pyruvate, 50 Iu ml–1 penicillin, 50 g ml–1 streptomycin
and 2 mM L-glutamine. HUVECs were grown in gelatine coated
flasks. Briefly, 5 ml gelatin was added to each tissue culture flask
and was allowed to coat the bottom. The flasks were then placed in
an incubator for 30 minutes after which time excess gelatin was
removed. Hanks’ balanced salts solution (HBSS) was used to wash
the flasks which were then ready for use. 
In order to assess the influence of vinflunine on apoptosis,
HUVECs were grown in gelatin coated 6-well plates and exposed
to 3 concentrations around the IC50 for tumour cells (Kruczynski 
et al, 1998b) for 4, 8 or 24 hours. Following incubation with the
drug, media were removed and kept and adherent cells were
detached from the wells with trypsin. These cells were added to the
previously collected media. Cells were pelleted by centrifugation
and resuspended in 50 ml HBSS. Cells were smeared on APES-
coated slides, allowed to dry and fixed in 95% ethanol for 20
minutes. Cell smears were placed in distilled water before staining
in a 1% solution of Hoechst 33342 for 20 minutes in the dark at
room temperature. After staining, slides were washed in distilled
water (2 minutes) and mounted with an aqueous mountant, glyc-
erol/PBS (Citifluor, Agar Scientific). Apoptotic cells were
detected by dark field, UV microscopy under oil (´1000). 
RESULTS 
Tumour growth studies 
The anti-tumour effects of test compounds against the MAC 15A
subcutaneous tumour are presented in Figure 1A. Each treatment
resulted in a statistically significant tumour growth delay and
although, from the figure, it appears that the highest dose of vinflu-
nine (60 mg kg–1)tested was more effective than the other treatments,
there was toxicity in this group. In this group, 2 out of 10 mice were
killed for humane reasons and there was an additional drug-associ-
ated death. There were also two drug-associated deaths in the
vinorelbine treated (10 mg kg–1) group. A second experiment
examined slightly lower doses of vinorelbine and vinflunine (8 and
50  mg kg–1 respectively) in an attempt to optimize the single dose
level and the results are presented as Figure 1B. Both these treat-
ments produced significant anti-tumour effects and vinflunine was
well tolerated with no obvious signs of toxicity at 50 mg kg–1..
However, vinorelbine treatment at this dose of 8 mg kg–1 still resulted
in definite body weight loss and obvious diarrhoea, although body
weights were recovering by the end of the experiments. 
Morphological effects 
Examination of histological sections of the tumours suggested that
treatment with either vincristine, vinorelbine or vinflunine all
caused an increase in the percentage of necrosis compared to
controls. In the untreated tumours most of the sections were of
normal healthy appearance (Figure 2). An example of the morpho-
logical appearance of the tumours from vincristine-treated (1.5 mg
kg–1) tumours is shown in  Figure 3 and although necrosis was
present, viable vasculature was easily definable. Haemorrhagic
necrosis was particularly obvious in the group of mice treated with
vinorelbine (10 mg kg–1) (Figure 4A) and was extensive in the
groups treated with vinflunine (50 mg kg21) (Figure 4B). There
was clear evidence of vascular damage in tumours taken from
mice treated with either vinorelbine (8 mg kg21) or vinflunine
(50 mg kg–1), as shown in Figure 5.
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orrhagic necrosis. Tumours treated with 10 mg kg–1 vinorelbine
showed a significantly increased percentage of necrosis at 71.0%
(SD 5.2). Treatment with 50 mg kg–1 vinflunine also resulted in a
significantly increased percentage of necrosis compared to the
controls and this value was marginally higher than that determined
for vinorelbine at 73.5% (SD 15.6). 
Vascular shutdown studies 
The fluorescent dye perfusion studies carried out confirmed our
earlier observation (Quinn et al, 1992; Cowen et al, 1995) that
control MAC 15A tumours were highly vascular. Analysis of
frozen sections of tumours from mice treated with vinflunine at
50 mg kg–1 indicated a very clear vascular shutdown within the
first 4 hours following treatment. This vascular shutdown
remained over the 24-hour period evaluated (Figure 6A). No fluo-
rescence was seen within the body of the tumours treated with this
dose of vinflunine (50 mg kg–1) and fluorescence was limited to
the tumour periphery. In the next series of experiments functional
vasculature was evaluated following administration of the 3 lower
doses of vinflunine ranging from 10 to 40 mg kg–1. Analysis of
frozen sections of control tumours for fluorescence indicated a
mean count for functional vascularity of 16.01% (Figure 6B).
Comparison with tumours taken from vinflunine-treated groups
of mice demonstrated vascular effects at each dose level
employed, although anti-vascular effects appeared more rapid
with increased dosage. A mean of only 1.03% (SD 3.86) func-
tional vasculature remained two hours after treatment with 10 mg
kg–1 vinorelbine.
Overall these data indicate that vinflunine caused vascular shut-
down in the transplantable murine adenocarcinoma model MAC
15A and these effects are obtained at doses below the optimum
effective dose. 
HUVEC assays 
4 and 8 hours after exposure to 0.05, 0.5 or 1 mM vinflunine,
HUVECs were not undergoing apoptosis although even at the
292 SE Holwell et al 
British Journal of Cancer (2001) 84(2), 290–295 © 2001 Cancer Research Campaign
5.0
4.0
3.0
2.0
0.9
1.0
0.8
0.7
0.6
0         1          2         3         4          5         6          7         8
5.0
4.0
3.0
2.0
0.9
1.0
0.8
0          1          2         3         4         5          6         7         8
R
e
l
a
t
i
v
e
 
t
u
m
o
u
r
 
v
o
l
u
m
e
(A)
R
e
l
a
t
i
v
e
 
t
u
m
o
u
r
 
v
o
l
u
m
e
(B)
Time (days)
Figure 1 (A) Anti-tumour effects of vinflunine, vinorelbine and vincristine 
in the MAC 15A subcutaneous tumour model; untreated controls (l),
1.5 mg kg–1 vincristine (n), 10 mg kg–1 vinorelbine (s), 20 mg kg–1 vinflunine
(t), 40 mg kg–1 vinflunine (u) and 60 mg kg–1 vinflunine (l). (B) Optimized
single dose concentrations of vinorelbine and vinflunine; untreated controls
(l), 8 mg kg–1 vinorelbine (n) and 50 mg kg–1 vinflunine (s). Points represent
mean  ±SEM 
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Figure 2 Morphological appearance of an untreated MAC 15A
subcutaneous tumour. T represents viable tumour, V indicates a blood vessel 
N
V
Figure 3 Morphological appearance of a MAC 15A tumour 24 hours after
treatment with 1.5 mg kg–1 vincristine. N indicates an area of necrosis,
V indicates a blood vessel lowest concentration, cell shape changes were evident. There was
clear evidence of apoptosis after 24 hours but only after exposure
to the highest (1 mM) concentration of vinflunine (Figure 7). 
DISCUSSION 
The Vinca alkaloid family is one of the principal groups of anti-
tumour compounds used routinely in the clinic today (Budman,
1992, 1997). Previously, members of this family such as
vincristine and vinblastine have been shown to mediate their anti-
tumour activities via an antivascular mechanism (Hill et al, 1993).
Novel derivatives of these compounds, namely vinorelbine and
vinflunine, have been shown to display significant antitumour
activity (Johnson et al, 1996; Kruczynski et al, 1998a; Hill et al,
1999). Indeed, vinorelbine is a clinically active compound and is
currently widely used in the treatment of cancer, especially in non-
small cell lung cancer and breast cancer (Berthaud et al, 1992;
Fumoleau et al, 1993; Le Chevalier et al, 1994; Romero et al,
1994; Fumoleau et al, 1995; Budman, 1997). Vinflunine is
currently in Phase I trials in Europe. Results presented here
demonstrate that both these new Vincas also mediate their anti-
tumour activities, at least in part, via an antivascular mechanism. 
In summary, the results indicate that vinflunine exerts antitu-
mour effects against the MAC 15A transplantable murine
adenocarcinoma model and is at least as effective as vincristine
and vinorelbine using single-dose schedules. Morphological
changes, particularly the appearance of haemorrhagic necrosis,
accompanying tumour growth delay suggested a possible anti-
vascular effect and this was confirmed by the Hoechst 33342
perfusion study that showed vascular shutdown over a minimum
of 24 hours. Vascular shutdown in the MAC 15A tumours was
obtained even at doses below the optimum effective single dose.
The potential importance of inducing vascular shutdown within
tumours at doses less than the maximum tolerated dose (MTD) has
been emphasized in studies of combretastatin A-4, which has been
shown recently to have a wide therapeutic window in several in
vivo experimental cancer models, including the MAC 15A murine
tumour tested here (Dark et al, 1997; Grosios et al, 1999; Tozer 
et al, 1999). In addition our results indicate that vinflunine appears
to demonstrate both enhanced antitumour activity and vascular
effects relative to vinorelbine. Combretastatin A-4 has been
demonstrated to induce endothelial cell shape changes in vitro
(Grosios et al, 1999) and similar changes in HUVEC shape were
observed in this study. However endothelial cell apoptosis
although clear at 24 hours did not occur following exposure to
vinflunine for up to 8 hours. Endothelial cell shape change rather
than apoptosis may be the primary event resulting in the rapid
vascular shutdown seen in tumours in vivo after treatment with
vinflunine. 
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Figure 4 (A) Morphological appearance of a MAC 15A tumour 24 hours
after treatment with 10 mg kg–1 vinorelbine . (B) Morphological appearance of
a MAC 15A tumour 24 hours after treatment with 50 mg kg–1 vinflunine. N
indicates an area of necrosis 
A
B
Figure 5 Vascular damage in tumours taken from mice treated with
(A) 8 mg kg–1 vinorelbine and (B) 50 mg kg–1 vinflunine294 SE Holwell et al 
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These data may have definite implications for combination
chemotherapy with vinflunine, since it may be possible to exploit
tumour blood flow changes so as to improve drug exposure charac-
teristics or to alter tumour microenvironmental properties for prodrug
activation. With regard to the development of an active
chemotherapy regimen, it would be advantageous to investigate these
potential anti-vascular effects in the current phase I/II clinical trials,
particularly since it has been demonstrated that vascular effects are
seen with vinflunine below the MTD. In fact earlier scheduling
experiments in mice bearing P388 leukaemia have shown that doses
of vinflunine up to 40 mg kg–1 per injection are effective in 2 weekly
or 4 weekly schedules up to a total dose of 240 mg kg–1 (Kruczynski
et al 1998a,b). Although the most effective schedule was 4 weekly
doses of 40 mg kg–1 totalling 160 mg kg–1.The present investigation
has indicated tumour vascular effects well below these doses.
Combination of vinflunine with other drugs with different mecha-
nisms of action at doses below their MTDs may thus result in a
synergy of action against the tumour with minimal host toxicity. 
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